Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa

NACompletedINTERVENTIONAL
Enrollment

804

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 7, 2023

Study Completion Date

October 24, 2023

Conditions
DengueChikungunyaMalaria
Interventions
DIAGNOSTIC_TEST

VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG

"For patients managed in an intervention site, a diagnostic test for dengue and chikungunya using VIDAS® as well as a screening test for malaria will be carried out. An awareness campaign on the use of VIDAS® diagnostic tests will be implemented as well.~The diagnosis will be based on the patient's clinical symptoms, the biological results of the VIDAS® tests for dengue and chikungunya, as well as the results of the tests for malaria."

OTHER

Standard of care practices

"For patients managed in a control site, the standard of care practices will be applied in the case of a febrile condition of undetermined etiology. This includes clinical diagnosis and, where appropriate, the use of routinely available diagnostic tests. At the end of the study, the collected samples will be tested using VIDAS® differential diagnosis tests to estimate the number of cases of dengue and chikungunya that have not been correctly diagnosed."

Trial Locations (3)

Unknown

Institut de Recherche en Sciences de la Santé, Ouagadougou

CHU Cocody, Abidjan

CHU Treichville, Abidjan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioMérieux

INDUSTRY